Identifying mutations in relapsed pediatric neuroblastoma may lead to better treatment options
the ONA take:
According to a new study published today in the journal Nature Genetics, researchers from various sites around the world have found that the majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling. Increased signaling in this pathway results in the progression of neuroblastoma.
"Our greater understanding of mutations on a crucial biological pathway offers prospects of acting on these pathways for direct benefit to children with this aggressive form of neuroblastoma," said senior author John M. Maris, M.D., a pediatric oncologist at The Children's Hospital of Philadelphia.
A class of drugs known as MEK inhibitors have demonstrated activity against this signaling pathway, suggesting that MEK inhibitors may benefit relapsed patients who possess mutations on the RAS-MAPK pathway.
Neuroblastoma is a solid tumor of the peripheral system that often grows in the chest or abdomen. It is the most common type of cancer in infants and is known for a high mortality rate in children. Most patients initially respond to chemotherapy, but many relapse and die from the disease.
Majority of pediatric patients with relapsed neuroblastoma studied harbored mutations that promoted RAS-MAPK pathway signaling.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|